Cuba encouraged by early efficacy results of homegrown COVID-19 vaccine – Reuters

A nurse shows a dose of the Soberana-02 COVID-19 vaccine to be utilized in a volunteer as part of Phase III trials of the speculative Cuban vaccine prospect, amid concerns about the spread of the coronavirus disease (COVID-19), in Havana, Cuba, March 31, 2021. Jorge Luis Banos/Pool through REUTERSHAVANA, June 19 (Reuters) – Cubas Soberana 2 vaccine prospect has actually shown 62% efficacy with just 2 of its three dosages, state-run biopharmaceutical corporation BioCubaFarma stated on Saturday, mentioning preliminary data from late phase trials.Cuba, whose biotech sector has actually exported vaccines for decades, has 5 vaccine prospects in scientific trials, of which two – Soberana 2 and Abdala – are in late phase trials. Iran began producing Soberana 2 earlier this year as part of late-phase medical trials.Cubas authorities have actually started administering the speculative vaccines en masse as part of “intervention research studies” they hope will slow the spread of the virus.Daily cases have actually halved in the capital given that the start of this vaccination project, according to official data, although that might likewise be due to stricter lockdown measures.Reporting by Anett Rios
Writing by Sarah Marsh; Editing by David GregorioOur Standards: The Thomson Reuters Trust Principles.

Leave a Reply

Your email address will not be published. Required fields are marked *